Two Cases of Adjuvant Immunotherapy with Cytokine-Induced Killer Cells for Relapsed or Refractory Neuroblastoma.
10.15264/cpho.2018.25.2.202
- Author:
Jung Yoon CHOI
1
;
Hong Yul AN
;
Kyung Taek HONG
;
Chery HONG
;
Hyoung Jin KANG
;
Hee Young SHIN
Author Information
1. Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul, Korea. hyshin@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Neuroblastoma;
Refractory;
Cytokine-induced killer cells
- MeSH:
Cytokine-Induced Killer Cells*;
Disease-Free Survival;
Humans;
Immunotherapy*;
Immunotherapy, Adoptive;
Neuroblastoma*
- From:Clinical Pediatric Hematology-Oncology
2018;25(2):202-207
- CountryRepublic of Korea
- Language:English
-
Abstract:
The treatment outcomes of relapsed or refractory neuroblastoma have been unsatisfactory till date. We reported two cases of adoptive immunotherapy using cytokine-induced killer (CIK) cells against relapsed or refractory neuroblastoma. CIK cell production was attempted in three patients, out of which two patients exhibited adequate levels of CIK cell production. Two patients completed full term of CIK cell infusions (weekly for 6 weeks and then biweekly for 8 wk) without serious adverse events. The progression-free survivals for the two patients were 1.9 and 4.1 months. Their overall survivals were 16.7 and 28.7 months. Although the efficacy was unclear, CIK cell infusion combined with other treatment strategies may have prolonged overall survival in refractory neuroblastoma patients. Further studies are needed to determine the exact role of CIK cell-based immunotherapy in relapsed or refractory neuroblastoma patients.
